Yili Chuanning Biotechnology Co., Ltd. logo

Yili Chuanning Biotechnology Co., Ltd. (301301)

Market Open
11 Aug, 06:57
XSHE XSHE
¥
9. 07
+0.03
+0.3319%
¥
23.33B Market Cap
- P/E Ratio
1.08% Div Yield
1.91M Volume
- Eps
¥ 9.04
Previous Close
Add Transaction
Day Range
8.97 9.1
Year Range
7.69 12.9
Want to track 301301 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

301301 trading today higher at ¥9.07, an increase of 0.3319% from yesterday's close, completing a monthly increase of 15.1015% or ¥1.19. Over the past 12 months, 301301 stock lost -10.5523%.
301301 is not paying dividends to its shareholders.
The last earnings report, released on Apr 10, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0561%, based on the last three reports.
Yili Chuanning Biotechnology Co., Ltd. has completed 1 stock splits, with the recent split occurring on Jun 10, 2020.
The company's stock is traded on one exchange.

301301 Chart

People also search for

Aier Eye Hospital Group Co. Ltd.
¥ 9.05
-0.2205%
Haisco Pharmaceutical Group Co., Ltd.
¥ 70.17
-0.1565%
Shannon Semiconductor Tech Inc.
¥ 155.64
-0.6384%
Sichuan Kelun Pharmaceutical Co., Ltd.
¥ 47.33
+1.9823%
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
¥ 27.47
-0.5431%

Yili Chuanning Biotechnology Co., Ltd. (301301) FAQ

What is the stock price today?

The current price is ¥9.07.

On which exchange is it traded?

Yili Chuanning Biotechnology Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 301301.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.08%.

What is its market cap?

As of today, the market cap is 23.33B.

Has Yili Chuanning Biotechnology Co., Ltd. ever had a stock split?

Yili Chuanning Biotechnology Co., Ltd. had 1 splits and the recent split was on Jun 10, 2020.

Yili Chuanning Biotechnology Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Xuheng Deng CEO
XSHE Exchange
CNE100005WX0 ISIN
CN Country
3,184 Employees
29 Apr 2026 Last Dividend
10 Jun 2020 Last Split
- IPO Date

Overview

Yili Chuanning Biotechnology Co.,Ltd. is a distinguished entity rooted in the bio-technological sphere within China, focusing extensively on the evolution and commercialization of biological fermentation technologies. Since its establishment in the year 2010, the company has anchored its operations in Yining, China, where it spearheads the development and application of cutting-edge biotechnological methods. The core of Yili Chuanning Biotechnology's operations lies in its steadfast dedication to innovation in the field of biotechnology, with a particular emphasis on the production of antibiotic intermediates through sophisticated fermentation processes.

Products and Services

Yili Chuanning Biotechnology offers a range of specialized products, primarily focusing on antibiotic intermediates. These products play a crucial role in the pharmaceutical industry, serving as foundational components for various antibiotics. Here's a closer look at the products offered:

  • Erythromycin Thiocyanate: This compound acts as a precursor for the production of erythromycin, a widely-used antibiotic for treating bacterial infections.
  • Penicillin G Potassium Salt: A fundamental intermediate used in the synthesis of penicillin-based antibiotics, crucial for combating bacterial infections.
  • 6-Aminopenicillanic Acid: This is an essential building block in the manufacture of penicillin derivatives, instrumental in the development of new antibiotic formulations.
  • 7-Aminocephalosporanic Acid: A key ingredient used for synthesizing cephalosporin antibiotics, known for their efficacy in treating a broad spectrum of bacterial infections.
  • 7-Aminodesacetoxycephalosporanic Acid: Another vital intermediate for cephalosporin antibiotics, aiding in the diversification of this antibiotic class for enhanced effectiveness.
  • Desacetyl-7-aminocephalosporanic Acid: This compound is utilized in modifying existing cephalosporin antibiotics to improve their pharmacological properties.
  • Ursodeoxycholic Acid: Beyond its role in antibiotic production, this acid is employed for its medicinal properties in treating liver diseases, showcasing the company's venture into therapeutic areas beyond antibiotics.

Contact Information

Address: No. 1 Gongchen Road, Yining, China, 835000
Phone: 86 28 8286 0516